Preclinical Evaluation of Novel SGLT2-Targeted Near-Infrared Optical Imaging Agent for Early-Stage Pulmonary Adenocarcinoma
These findings support the potential of GlucoGlo as a targeted IMI contrast agent for early-stage LUAD, and they provide a foundation for future in vivo studies and translational development.
Authors
- Lydia Y. Chen (ORCID: https://orcid.org/0000-0002-4228-6735)
- Michael C. Brown (ORCID: https://orcid.org/0000-0002-3957-1164)
- David E. Holt (ORCID: https://orcid.org/0000-0002-8819-7738)
- Venugopal Bandi (ORCID: https://orcid.org/0000-0003-3602-9641)
- Kelly McGovern (ORCID: https://orcid.org/0000-0002-0267-8646)
- Kevin Guo (ORCID: https://orcid.org/0000-0002-5893-2164)
- Katherine O. Welch
- Ryan Krouse (ORCID: https://orcid.org/0009-0006-8350-1717)
- Paul J. Zhang (ORCID: https://orcid.org/0000-0002-3615-9094)
- Joseph Mlakar
- Sunil Singhal (ORCID: https://orcid.org/0000-0002-2413-7082)
- Jeffrey Huang (ORCID: https://orcid.org/0000-0002-7478-101X)
Institutions
- Hospital of the University of Pennsylvania (US)
Publication Details
- Journal
- Molecular Imaging and Biology
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1007/s11307-025-02029-w
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Cancer Institute